...
首页> 外文期刊>ACS Omega >Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3
【24h】

Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3

机译:吡啶并咪唑支架的结构优化:将选择性从p38α丝裂原活化的蛋白激酶转移到c-Jun N端激酶3

获取原文
           

摘要

Starting from known p38α mitogen-activated protein kinase (MAPK) inhibitors, a series of inhibitors of the c-Jun N-terminal kinase (JNK) 3 was obtained. Altering the substitution pattern of the pyridinylimidazole scaffold proved to be effective in shifting the inhibitory activity from the original target p38α MAPK to the closely related JNK3. In particular, a significant improvement for JNK3 selectivity could be achieved by addressing the hydrophobic region I with a small methyl group. Furthermore, additional structural modifications permitted to explore structure–activity relationships. The most potent inhibitor 4-(4-methyl-2-(methylthio)-1H-imidazol-5-yl)-N-(4-morpholinophenyl)pyridin-2-amine showed an IC50 value for the JNK3 in the low triple digit nanomolar range and its binding mode was confirmed by X-ray crystallography.
机译:从已知的p38α丝裂原活化蛋白激酶(MAPK)抑制剂开始,获得了一系列c-Jun N端激酶(JNK)3抑制剂。事实证明,改变吡啶基咪唑骨架的取代模式可有效地将抑制活性从最初的靶标p38αMAPK转移到紧密相关的JNK3。特别地,通过用小的甲基处理疏水区I可以实现对JNK3选择性的显着改善。此外,还可以进行其他结构修改以探索结构与活动的关系。最有效的抑制剂4-(4-甲基-2-(甲硫基)-1H-咪唑-5-基)-N-(4-吗啉代苯基)吡啶-2-胺显示JNK3的IC50值处于低三位数X射线晶体学证实了纳摩尔范围及其结合模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号